Biontech Se ADR (BNTX)

$133.33 0.00 (0.00%)

16:00 EDT BNTX Stock Quote Delayed 30 Minutes

7 Stocks Set to Soar When the Market Recovers

By Josh Enomoto, InvestorPlace Contributor Mar 16, 2023

Although investors are freaking out over the banking sector fallout, bold contrarians may consider these stocks to buy.

The 3 Most Undervalued Growth Stocks for Your February Buy List

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

Thursday Predictions: 3 Hot Stocks for Tomorrow

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 181

Day's Range -

52-Week Range $117.08 - $189.07

Dividend & Yield N/A (N/A)

BNTX Stock Predictions, Articles, and Biontech Se ADR News

From InvestorPlace
From the Web

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

By Thomas Niel, InvestorPlace Contributor Dec 18, 2022

As their respective catalysts (namely new treatments/products) continue to play out, each one of these seven hottest healthcare stocks has a strong chance of making another significant move higher in 2023, and in the years ahead.

7 Stocks on the Perfect 10 List

By Chris Lau, InvestorPlace Contributor Nov 23, 2022

Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential.

7 Stocks to Sell Right Now… and 1 to Buy

By Josh Enomoto, InvestorPlace Contributor Nov 18, 2022

Although red ink can sometimes bring an opportunity for contrarianism, these (except one) market ideas represent stocks to sell.

The 7 Best Pharma Stocks to Buy Now

By Joel Baglole, InvestorPlace Contributor Nov 8, 2022

Oil and natural gas stocks are not the only ones to post big gains this year. Several pharmaceutical stocks have rallied 30% or more as sales of their blockbuster medications, including Covid-19 vaccines, supercharge their earnings.

Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?

By Bret Kenwell, InvestorPlace Contributor Oct 21, 2022

Vaccine stocks are flying higher on Friday on word that Pfizer will quadruple the price of its Covid-19 vaccine. Will others follow suit?

7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’

By Chris Lau, InvestorPlace Contributor Sep 27, 2022

Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over.

Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?

By Bret Kenwell, InvestorPlace Contributor Sep 19, 2022

Vaccine stocks are taking it on the chin following President Biden's comments that the "pandemic is over." What now?

Why Is BioNTech (BNTX) Stock Down 7% Today?

By William White, InvestorPlace Writer Aug 8, 2022

BioNTech (BNTX) stock is on falling on Monday after the company released poor earnings results for its second quarter of 2022.

7 Biotech Stocks With Key Catalysts Coming in July

By Tezcan Gecgil, InvestorPlace Contributor Jun 27, 2022

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon

7 Long-Term Stocks to Buy in a Bear Market

By Stavros Georgiadis, CFA, InvestorPlace Contributor Jun 20, 2022

These long-term stocks to buy are from defensive sectors, because now is the time to play defense in your stock investing.

7 of the Best Cheap Stocks to Buy for the Second Half of 2022

By Tezcan Gecgil, InvestorPlace Contributor May 25, 2022

These are the best cheap stocks to invest in now. They all offer compelling buying opportunities in today's volatile market.

BNTX Stock Treks Higher on BioNTech’s Vaccine Sales

By Larry Ramer, InvestorPlace Contributor May 9, 2022

BNTX stock is climbing on Monday after BioNTech reported better-than-expected results. The company credits Covid-19 vaccine innovation.

7 Top-Rated Biotech Stocks to Buy for Q2

By Louis Navellier and the InvestorPlace Research Staff Apr 21, 2022

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

4 Undervalued Biotech Stocks to Add to Your Buy List

By Shanthi Rexaline Apr 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.